Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study

Autor:	Boudou-Rouquette, Pascaline, Arrondeau, Jennifer, Gervais, Claire, Durand, Jean-Philippe, Fabre, Elizabeth, De Percin, Sixtine, Villeminey, Clémentine Vaquin, Piketty, Anne-Catherine, Rassy, Nathalie, Ulmann, Guillaume, Damotte, Diane, Mansuet-Lupo, Audrey, Giraud, Frédérique, Alifano, Marco, Wislez, Marie, Alexandre, Jérôme, Jouinot, Anne, Goldwasser, François
Zdroj:	In EBioMedicine November 2021 73
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu